An FDA advisory committee has recommended the development of next year's flu vaccine, as new data from the CDC indicates the current 2025-2026 flu vaccine provides moderate protection against hospitalization for vaccinated individuals despite concerns about late-emerging H3N2 strains. The committee reviewed winter flu shot effectiveness reports published in the CDC's online MMWR journal, which showed moderate protective efficacy against severe outcomes requiring hospitalization. The timing of vaccine selection remains critical as late-emerging H3N2 variants can significantly undermine vaccine effectiveness, a concern flagged by the committee during this year's review. Current guidance continues to emphasize vaccination for those at high risk of severe illness, particularly elderly and immunocompromised populations.